Obesity is increasingly referred to as a chronic disease. This is also how it is defined in the recommendations of scientific ...

By Michele Gershberg and Michael Erman PHILADELPHIA, March 16 (Reuters) - The CEO of Roche's Genentech unit, Ashley Magargee, ...

The 2013 declaration of obesity as a chronic disease and the 2021 approval of semaglutide are associated with increased use ...

As obesity medicine continues to evolve, integrating sleep health into obesity treatment plans is essential.Poor sleep ...

AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs top healthcare stocks. On March 9, William Blair reiterated an Outperform rating on AbbVie Inc. (NYSE:ABBV). The research firm remains confident about ...

Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...

According to the Gallup National Health and Well-Being Index, 37% of U.S. adults now report obesity, down from 39.9% three ...

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...

Acetazolamide plus atomoxetine improved nocturnal CO2 and oxygenation in OHS. Find out more about this proof-of-concept trial ...

A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent ...

Long-acting injectable CAB+RPV maintains high virologic suppression in patients with HIV and obesity, showing comparable real-world efficacy.

By Michele Gershberg and Michael Erman PHILADELPHIA, March 16 (Reuters) - The CEO of Roche's Genentech unit, Ashley Magargee, ...